Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.27 · Revenue $147.28M · 4 analysts
Est. EPS $-0.23 · Revenue $171.81M · 4 analysts
Est. EPS $-0.74 · Revenue $620.59M · 7 analysts
Est. EPS $-0.12 · Revenue $161.49M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $642.8M | +5.2% | +0.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-43.5M | +76.2% | -33.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +69.1% | +1.8% | +5.8% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -17.2% | +45.8% | -14.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -6.8% | +77.3% | -32.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $130.1M | +2371.2% | -37.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +20.2% | +2258.0% | -37.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 19.8% | +70.3% | -4.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.46x | -10.2% | -3.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.0B | +13.4% | +1.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.35 vs -0.43 | +17.9% | -0.14 vs -0.27 | +47.5% |
| Revenue Surprise | $642.8M vs $636.4M | +1.0% | $151.0M vs $147.3M | +2.5% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Saxonov Serge | director, officer: Chief Executive Officer | Class A Common Stock | D | 100 | — |
| Aug 26, 2026 | Saxonov Serge | director, officer: Chief Executive Officer | Class A Common Stock | D | 3,500 | $63.02 |
| Aug 26, 2026 | Saxonov Serge | director, officer: Chief Executive Officer | Class A Common Stock | D | 6,494 | $63.98 |
| Aug 26, 2026 | Saxonov Serge | director, officer: Chief Executive Officer | Class A Common Stock | D | 492 | $64.75 |
| Aug 24, 2026 | Saxonov Serge | director, officer: Chief Executive Officer | Class A Common Stock | D | 18,545 | $63.02 |
Operator: Hello, everyone. Thank you for joining us, and welcome to the 10x Genomics Second Quarter 2026 Earnings Conference Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Cassie Corneau, Head of Investor Relations and Strategic Finance. Please go ahead. Cassie Corneau: Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the second quarter ended June 30th, 2026. If you have not received this news release or would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of Federal Securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10x Genomics issued today, and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Joining the call today are Serge Saxonov, our CEO and Co-founder, and Adam Taich, our Chief Financial Officer. We will host a question and answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue. With that, I will now turn the call over to Serge. Serge Saxonov: Thanks, Cassie, and good afternoon, everyone. I will start with a brief overview of our second quarter performance, then provide an update on Atera, and finally discuss several broader trends that are reshaping biological research and creating new opportunities for our business. Revenue for the second quarter was $151 million. During the quarter, we recognized $1.6 million of license and royalty revenue in connection with our settlement with Takara. Excluding non-recurring settlement revenue in both this quarter and the prior year period, Q2 revenue was $149 million and grew 3% YoY. The story of the quarter was the extraordinary customer response to Atera. We're highly encouraged by the engagement across the research ecosystem and the very strong early order flow. At the same time, our own market products showed sustained strength. We drove …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Serge Saxonov | Co-Founder, Chief Executive Officer & Director | USD 1,308,975 | — | 1977 | Active |
Benjamin J. Hindson | Co-Founder, President, Chief Scientific Officer & Director | USD 811,604 | — | 1975 | Active |
Adam S. Taich | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer | USD 792,041 | Male | 1975 | Active |
Mennah Moustafa | Chief Commercial Officer | USD 390,782 | Female | — | Active |
Randy Wu | General Counsel and Secretary | — | — | — | Active |
Jens Durruthy | Associate Director of Product Management | — | Male | — | Active |
Jim Goodrich | Chief of Global Operations | — | Male | — | Active |
Michael Schnall-Levin | Founding Scientist & Chief Technology Officer | — | Male | — | Active |
Cassie Corneau | Manager of Investor Relations & Strategic Finance | — | Female | — | Active |
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms PLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Lausanne University Hospital (CHUV), one of Switzerland's leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care.
Amova Asset Management Americas Inc. cut its holdings in shares of 10x Genomics (NASDAQ: TXG) by 7.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,104,178 shares of the company's stock after selling 381,975 shares during the period. 10x
Mitesco (OTCMKTS:MITI - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Profitability This table compares Mitesco and 10x Genomics' net
